# Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

> **NCT02212561** · PHASE1 · COMPLETED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 19 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Acute Lymphoblastic Leukemia (ALL)
- Myelodysplastic Syndrome (MDS)
- Mixed Phenotype Acute Leukemia (MPAL)

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Fludarabine
- **DRUG:** Cytarabine
- **DRUG:** methotrexate/hydrocortisone/cytarabine

## Key facts

- **NCT ID:** NCT02212561
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2020-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02212561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02212561, "Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02212561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*